Leptospirosis

Scholars have expressed that Leptospirosis is zoonotic disease that is caused by pathogenic bacteria of the Leptospira genus and also happens to be extremely dangerous and acute. A wide variety of therapies for Leptospirosis and the vaccines for the disease for therapeutics development are offered by us.

Overview of Leptospirosis

The genus Leptospira has now 68 recognized species, many of them are parasitic in diverse Mams, including human. Leptospira pathogen is usually present in the urine of infected rats and is contacted in humans both directly and indirectly. Leptospira bacteria in humans, can rapidly be disseminated throughout the body through the circulation to well vascular lied parts such as the liver and kidney which in turn result into the symptoms of leptospirosis.

Fig.1 Current and potential therapeutic options for leptospirosis. (Petakh P., et al., 2024)

Vaccine Development for Leptospirosis

Scientific Challenges in Vaccine Development

The combined presence of more than 300 serovars and 24 serological partners implies the existence of a polymorphic Leptospira species. The advanced structure of the Leptospira disease-causing organisms assists in its ability to infect various hosts without being recognized by the hosts immune system. It is normal to find newer vaccines in companion animal medicine however, developing a cross protective vaccine for humans is indeed an arduous task.

Advances in Vaccine Candidates

In the past decades, efforts have been targeted into mining of bioinformatics and reverse vaccinology for new protein targets' data. Due to their surface availability and phylogenetic conservation among pathogenic species, the leptospiral immunoglobulin-like (Lig) proteins are very appealing. Also, the search for live-attenuated vaccines has been fruitful, with the reports of effectiveness and cross-protection.

Therapeutics Development for Leptospirosis

Our Services

Strong investment in new scientific approaches, combined with a clear understanding of leptospirosis pathogenesis, puts penetration due to this disease. We seek to deliver comprehensive solutions for international pharmaceutical manufacturers through our preclinical research and development services.

Vaccine Development

• Live-attenuated Vaccine
• Inactivated Vaccine
• Toxoid Vaccine
• Viral Vector Vaccine
• Virus-like Particles Vaccine
• Protein Subunit Vaccine
• mRNA Vaccine
• DNA Vaccine

Therapeutic Development

• Small Molecule Drug Development Services
• Therapeutic mRNA Development Services
• Therapeutic Antibody Development Services
• Cell Therapy Development Services

Infectious Disease Models

• Lethal Leptospirosis Models (Adult C57BL/6 mice deficient in TLR4 or MyD88)
• Sublethal Leptospirosis Models (A, CBA, BALB/c, C57BL/6, and C3H-HeJ mouse strains)
• Chronic Leptospirosis Models (Rattus norvegicus)

To begin with, we offer the most comprehensive range of preclinical research services – identification of novel vaccine candidates through reverse vaccinology and evaluation of their immunogenicity and protective efficacy in animal models. If you are interested in the types of services we provide, please feel free to reach out to us to get more details and an appropriate quote.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.